Key Points for Monitoring Drug Clinical Evaluation and Anticancer Drug Price Reduction by Health and Health Commission

 Key Points for Monitoring Drug Clinical Evaluation and Anticancer Drug Price Reduction by Health and Health Commission

Information Picture Xinhua reporter Zhang Nizhao

The Circular of the State Health and Health Commission clearly stated that all public medical and health institutions should systematically collect and report information on the variety of drugs, production enterprises, quantity of drugs used, purchase price, supply and distribution; give full play to the role of national and provincial medical institutions, scientific research institutes, trade associations and other institutions to propel the comprehensive evaluation of drugs in a sound and orderly manner, and highlight the clinical value of drugs. To promote the use of relevant evidence for national essential drugs, encourage generic drugs, encourage the selection and dynamic adjustment of childrens drug declarations.

The circular pointed out that relying on the national health insurance information project and the regional national health information platform, the national and provincial drug use monitoring platform and the national, provincial, prefectural and county level drug use monitoring network should be established to realize the functions of drug use information collection, statistical analysis and information sharing. More than 1500 public health institutions at all levels in China were selected to monitor the specific data related to drug use, disease prevention, follow-up and follow-up.

In 2019, the pilot provinces of the first phase of the National Health Insurance Informatization Project, the pilot cities of centralized drug procurement organized by the state, and the key monitoring medical and health institutions in all provinces (districts and municipalities) should focus on the monitoring of drug use with the focus on the national essential drugs, the drugs for the special work of reducing the price of anticancer drugs and the pilot varieties of centralized drug procurement organized by the state.

In 2020, the monitoring scope basically covers secondary and above public medical institutions, and extends to primary medical and health institutions, gradually realizing the monitoring of all equipped and used drugs. Health administrative departments and medical and health institutions at all levels should strengthen the analysis and utilization of monitoring information, regularly form monitoring reports, strengthen communication and coordination with departments such as industry and credit, medical insurance, drug supervision and centralized drug procurement agencies, and strengthen data and information co-construction, sharing and sharing.

In addition, the notification made it clear that the State would entrust relevant technical institutions or trade associations to formulate technical specifications such as methods and standards for clinical comprehensive evaluation of drugs and establish expert committees for clinical comprehensive evaluation. Provincial health administrative departments should conduct a summary and analysis of the development situation in their jurisdictions every year, so as to grasp the promotion and implementation situation in time.

According to the requirements, health administrative departments at all levels should scientifically use the results of comprehensive evaluation of drugs, guide drug procurement in medical institutions and drug use linkages between higher and lower medical institutions, optimize drug use structure in medical institutions, put forward suggestions on drug price policy and drug production incentive and support policy in national essential drug catalogue, control unreasonable drug expenditure, and put forward suggestions for improving drug use. Suggestions on rationalization of types, specifications and packaging should be made to guide enterprises to develop and produce drugs suitable for clinical needs.